FDA approves oral therapy for acromegaly

The U.S. Food and Drug Administration (FDA) has approved octreotide (MYCAPSSA) capsules for long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide. This is the first and only oral somatostatin analog (SSA) approved by the FDA.

“People living with acromegaly experience many challenges associated with injectable therapies and are in need of new treatment options,” said Jill Sisco, president of the Acromegaly Community, Inc, in a press release from Chiasma, Inc. “The entire acromegaly community has long awaited oral therapeutic options and it is gratifying to see that the FDA has now approved the first oral SSA therapy with the potential to make a significant impact in the lives of people with acromegaly and their caregivers.”

Read the full press release here.